Centerline Wealth Advisors LLC Invests $213,000 in Johnson & Johnson (NYSE:JNJ)

Centerline Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 1,474 shares of the company’s stock, valued at approximately $213,000.

Other large investors have also added to or reduced their stakes in the company. Live Oak Private Wealth LLC raised its holdings in shares of Johnson & Johnson by 1.8% during the fourth quarter. Live Oak Private Wealth LLC now owns 6,743 shares of the company’s stock valued at $975,000 after acquiring an additional 116 shares in the last quarter. Global X Japan Co. Ltd. raised its holdings in Johnson & Johnson by 17.7% in the 4th quarter. Global X Japan Co. Ltd. now owns 3,178 shares of the company’s stock worth $460,000 after purchasing an additional 478 shares in the last quarter. Prairie Wealth Advisors Inc. lifted its position in shares of Johnson & Johnson by 2.8% in the 4th quarter. Prairie Wealth Advisors Inc. now owns 3,061 shares of the company’s stock worth $443,000 after purchasing an additional 84 shares during the period. Beese Fulmer Investment Management Inc. increased its position in shares of Johnson & Johnson by 0.7% during the fourth quarter. Beese Fulmer Investment Management Inc. now owns 125,953 shares of the company’s stock valued at $18,215,000 after buying an additional 869 shares during the period. Finally, Fairvoy Private Wealth LLC bought a new position in Johnson & Johnson in the fourth quarter worth about $234,000. Institutional investors own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

JNJ has been the topic of a number of research analyst reports. Citigroup reduced their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a report on Wednesday, December 11th. Wells Fargo & Company decreased their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Guggenheim upped their price objective on shares of Johnson & Johnson from $162.00 to $166.00 and gave the stock a “neutral” rating in a report on Monday, February 3rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $170.67.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of the stock in a transaction dated Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Price Performance

NYSE JNJ opened at $154.22 on Tuesday. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. The company has a market capitalization of $371.31 billion, a price-to-earnings ratio of 23.19, a PEG ratio of 2.46 and a beta of 0.52. The stock has a 50-day moving average of $147.42 and a 200 day moving average of $156.08. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The firm’s quarterly revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the company posted $2.29 earnings per share. On average, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 3.22%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.